References

Balasubramaniam K, Grambsch PM, Wieser RH, Lindor KD, Dickson ER. Diminished survival in asymptomatic primary biliary cirrhosis: A prospective study. *Gastroenterology*. 1990;98(6):1567-1571.

Beuers U, Gershwin ME, Gish RG, et al. Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'. *Hepatology*. 2015;62(5):1620-1622.

Carey EJ, Ali AH, Lindor KD. Primary biliary cirrhosis. *Lancet*. 2015;386(10003):1565-1575.

Chatzipantelis P, Giatromanolaki A. Early histopathologic changes in primary biliary cholangitis: does 'minimal change' primary biliary cholangitis exist? A pathologist's view. *Eur J Gastroenterol Hepatol*. 2021;33(12):e7-e12.

Colapietro F, Bertazzoni A, Lleo A. Contemporary epidemiology of primary biliary cholangitis. *Clin Liver Dis*. 2022;26(4):555-570.

Corrigan M, Hirschfield G, Greenfield S, Parry J. Barriers to implementation of stratified care in primary biliary cholangitis: a scoping exercise. *BMJ Open Gastroenterol*. 2019;6(1):e000226.

D'Amato D, De Vincentis A, Malinverno F, et al. Real-world experience with obeticholic acid in patients with primary biliary cholangitis. *JHEP Rep*. 2021;3:100248.

Dickson ER, Grambsch PM, Fleming TR, Fisher LD, Langworthy A. Prognosis in primary biliary cirrhosis: model for decision making. *Hepatology*. 1989;10(1):1-7.

European Association for the Study of the Liver. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. *J Hepatol*. 2017;67(1):145-172.

Francisco A, Shah S, Heneghan M, Joshi D. P30 Is a virtual pharmacy-led hub and spoke model effective in managing primary biliary cholangitis with obeticholic acid? *Gut*. 2020;69:A21.

Gao Y, Li L, Li B, Zhan Y. Response rate and impact on lipid profiles of obeticholic acid treatment for patients with primary biliary cholangitis: a meta-analysis. *Can J Gastroenterol Hepatol*. 2021;2021:8829510.

Gibbons C, Srinavasan S, Bodhani J, Li J, Chen L, Trivedi P. Analyses of obeticholic acid treatment retention in UK patients based on medicine delivery data. *J Hepatol*. 2022;77(1):S310. Abstract THU438.

Hirschfield GM, Dyson JK, Alexander GJM, et al. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines. *Gut*. 2018;67:1568–1594.

Italian PBC Registry and the Club Epatologi Ospedalieri (CLEO)/Associazione Italiana Gastroenterologi ed Endoscopisti Digestivi Ospedaliere (AIGO) PBC Study Group. Real-world experience with obeticholic acid in patients with primary biliary cholangitis. *JHEP Rep*. 2021;3(2):100248.

Kaplan MM, Gershwin ME. Primary biliary cirrhosis. *N Engl J Med*. 2005;353(12):1261-1273.

Kim WR, Lindor KD, Locke GR, et al. Epidemiology and natural history of primary biliary cirrhosis in a US community. *Gastroenterology*. 2000;119(6):1631-1636.

Kumagi T, Guindi M, Fischer SE, et al. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. *Am J Gastroenterol*. 2010;105(10):2186-2194.

Kuiper EM, Hansen BE de Vries RA, et al for the Dutch PBC Study Group. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. *Gastroenterology*. 2009;136(4):1281-1287.

Lammers WJ, van Buuren HR, Hirschfield GM, et al for the Global PBC Study Group. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. *Gastroenterology*. 2014;147(6):1338-1349.

Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. *Hepatology*. 2019;69:394-419.

Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: 2021 practice guidance update from the American Association for the Study of Liver Diseases. *Hepatology*. 2022;75:1012-1013.

Liu BD, Qureshi K. Secondary treatment of primary biliary cholangitis: early prediction of inadequate response to ursodeoxycholic acid in patients with PBC. *Dig Dis Sci*. 2022. Published online September 13, 2022.

Lleo A, Battezzati PM, Selmi C, Gershwin ME, Podda M. Is autoimmunity a matter of sex? *Autoimmun Rev*. 2008;7(8):626-630.

Miyakawa H, Tanaka A, Kikuchi K, et al. Detection of antimitochondrial autoantibodies in immunofluorescent AMA-negative patients with primary biliary cirrhosis using recombinant autoantigens. *Hepatology*. 2001;34(2):243-248.

Muratori P, Muratori L, Ferrari R, et al. Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis. *Am J Gastroenterol*. 2003;98(2):431-437.

Newton JL, Gibson GJ, Tomlinson M, Wilton K, Jones D. Fatigue in primary biliary cirrhosis is associated with excessive daytime somnolence. *Hepatology*. 2006;44(1):91-98.

Perez CFM, Adekunle F, Mayne T, et al. Long-term obeticholic acid (OCA) for primary biliary cholangitis (PBC) in a clinical trial improved event free survival (death, liver transplant and hepatic decompensation) compared to external controls from the GLOBAL PBC real-world database. *J Hepatol*. 2022;77(1):S333. Abstract THU484

Prince MI, Chetwynd A, Craig WL, Metcalf JV, James OF. Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort. *Gut*. 2004;53(6):865-870.

Roll J, Boywer JL, Barry D, Klatskin G. The prognostic importance of clinical and histological features in asymptomatic and symptomatic primary biliary cirrhosis. *N Engl J Med*. 1983;308(1):1-7.

Selmi C, Bowlus CL, Gershwin ME, Coppel RL. Primary biliary cirrhosis. *Lancet*. 2011;377(9777):1600-1609.

Smith A, Giles B, Aspinall RJ. Primary biliary cholangitis: advances in understanding and management. *Br J Hosp Med*. 2022;83(3):1-9.

Sorokin A, Brown JL, Thompson PD. Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review. *Atherosclerosis*. 2007;194(2):293-299.

Tornay AS Jr. Primary biliary cirrhosis: natural history. *Am J Gastroenterol*. 1980;73(3):223-226.

Van de Water J, Cooper A, Surh CD, et al. Detection of autoantibodies to recombinant mitochondrial proteins in patients with primary biliary cirrhosis. *N Engl J Med*. 1989;320(21):1377-1380.

Xiang X, Yang X, Shen M, et al. Ursodeoxycholic acid at 18-22mg/kg/d showed a promising capacity for treating refractory primary biliary cholangitis. *Can J Gastroenterol Heptaol*. 2021;2021:6691425.